{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:12Z","timestamp":1793386752719,"version":"4.5.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeOne Medicines, Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/17474086.2026.2628549","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:47:11Z","timestamp":1770666431000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma"],"prefix":"10.1080","volume":"19","author":[{"given":"Javier","family":"Pinilla-Ibarz","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center & Research Institute","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wu","sequence":"additional","affiliation":[{"name":"Real Chemistry","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Esselman","sequence":"additional","affiliation":[{"name":"Real Chemistry","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Furnback","sequence":"additional","affiliation":[{"name":"Real Chemistry","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Challagulla","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59259-963-9_82"},{"key":"e_1_3_7_3_1","unstructured":"National Organization for Rare Disorders. Chronic lymphocytic leukemia - symptoms causes treatment January 12. 2023 [cited 2024 Mar 7]. Available from: https:\/\/rarediseases.org\/rare-diseases\/chronic-lymphocytic-leukemia\/"},{"key":"e_1_3_7_4_1","unstructured":"National Cancer Institute. NCI dictionary of cancer terms. [cited 2023 Mar 7]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/cll-sll"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_3_7_6_1","unstructured":"Cancer.org. Key Statistics for Chronic Lymphocytic Leukemia. 2023 [cited 2023 Mar 7]. Available from: https:\/\/www.cancer.org\/cancer\/types\/chronic-lymphocytic-leukemia\/about\/key-statistics.html#:~:text=The%20American%20Cancer%20Society\u2019s%20estimates About%204%2C440%20deaths%20from%20CLL"},{"key":"e_1_3_7_7_1","unstructured":"National Comprehensive Cancer Network (NCCN). Chronic lymphocytic leukemia\/small lymphocytic lymphoma (version 3.2023). 2023. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-585067"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad324"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2331631"},{"key":"e_1_3_7_11_1","unstructured":"FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma"},{"key":"e_1_3_7_12_1","unstructured":"FDA takes second action under international collaboration approves new treatment option for patients with chronic lymphocytic leukemia. 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients"},{"key":"e_1_3_7_13_1","unstructured":"Foundation LR. Chronic lymphocytic leukemia\/small lymphocytic lymphoma: FDA updates. 2024 [cited 2024 Jul 26]. Available from: https:\/\/www.lymphoma.org\/understanding-lymphoma\/aboutlymphoma\/cll\/cllfdaupdates\/"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012221"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7500"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174289"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251340554"},{"key":"e_1_3_7_20_1","volume-title":"European Hematology Association 2024 Congress","author":"Shadman M","year":"2024","unstructured":"Shadman M, Bouwmeester W, Mohseninejad L, et al. Zanubrutinib versus other bruton tyrosine kinase inhibitors in relapsed\/refractory chronic lymphocytic leukemia: a multilevel network meta-regression [Poster presentation]. In: European Hematology Association 2024 Congress; Madrid, Spain; 2024."},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7048"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012142"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02035"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.010"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7467"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3855"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2856"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2200167"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2268"},{"issue":"4","key":"e_1_3_7_30_1","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado A","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121\u20131131.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178058"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23263"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174915"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11158"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207760"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23271"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23264"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009739"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167213"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0436"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193298"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198915"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2628549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:39:17Z","timestamp":1775039957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2628549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/17474086.2026.2628549"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2628549","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}